STOCK TITAN

Director Mary Thistle receives 9,810 Q32 Bio (QTTB) stock options at $12.64

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Q32 Bio Inc. director Mary Thistle received a grant of stock options representing 9,810 shares of common stock. These options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, she holds 9,810 options directly.

The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, as long as she continues serving on the board through that vesting date.

Positive

  • None.

Negative

  • None.
Insider Thistle Mary
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,810 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,810 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 9,810 options Stock Option (Right to Buy) grant to director
Exercise price $12.64 per share Exercise price of granted stock options
Expiration date June 11, 2036 Option term end date
Underlying shares 9,810 shares Common stock underlying granted options
Post-grant derivative holdings 9,810 options Total options held following transaction
Vesting trigger date June 12, 2027 Earlier of this date or next annual meeting
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 12.6400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders"
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thistle Mary

(Last)(First)(Middle)
Q32 BIO INC.
830 WINTER STREET

(Street)
WALTHAM MASSACHUSETTS 02451

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$12.6406/12/2026A9,810 (1)06/11/2036Common Stock9,810$09,810D
Explanation of Responses:
1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
/s/ Eric Bell, Attorney-in-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Q32 Bio (QTTB) report for Mary Thistle?

Q32 Bio reported that director Mary Thistle received a grant of stock options for 9,810 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of Mary Thistle’s new Q32 Bio (QTTB) stock options?

The granted stock options have an exercise price of $12.64 per share. This means Thistle can buy Q32 Bio common stock at $12.64 per share once the options vest and become exercisable.

When do Mary Thistle’s Q32 Bio (QTTB) stock options vest and become exercisable?

The options vest in full on the earlier of June 12, 2027 or Q32 Bio’s next annual meeting of stockholders. Vesting is conditioned on her continued service as a director through that date.

How many Q32 Bio (QTTB) options does Mary Thistle hold after this grant?

After this transaction, Mary Thistle holds 9,810 stock options directly. These options each relate to one share of Q32 Bio common stock and reflect her position following the reported grant.

Are Mary Thistle’s Q32 Bio (QTTB) option grants open-market purchases or sales?

No. The filing describes a grant/award acquisition of stock options as compensation. It is not classified as an open-market buy or sell and carries a transaction code of A for award.